Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P2 alpelisib in PIK3CA-related overgrowth spectrum
2020-000561-16Phase 2Active
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in PIK3CA-related overgrowth spectrum (PROS) comparing alpelisib with placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2020; status: active.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on 2020-000561-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000561-16.